2 February 2022 - - Researcher led by NYU Grossman School of Medicine and Columbia University has discovered a mechanism that may explain why COVID-19 patients lose their sense of smell, the principals said.

Published online February 2 in the journal Cell, the new study found that infection with the pandemic virus, SARS-CoV-2, indirectly dials down the action of olfactory receptors, proteins on the surfaces of nerve cells in the nose that detect the molecules associated with odors.

Led by researchers from NYU Grossman School of Medicine and Columbia University, the new study may also shed light on the effects of COVID-19 on other types of brain cells, and on other lingering neurological effects of COVID-19 like "brain fog," headaches, and depression.

Experiments showed that the presence of the virus near nerve cells (neurons) in olfactory tissue brought an inrushing of immune cells, microglia and T cells, that sense and counter infection.

Such cells release proteins called cytokines that changed the genetic activity of olfactory nerve cells, even though the virus cannot infect them, say the study authors.

Where immune cell activity would dissipate quickly in other scenarios, in the brain, according to the team's theory, immune signaling persists in a way that reduces the activity of genes needed for the building of olfactory receptors.

One unique symptom of COVID-19 infection is loss of smell without the stuffy nose seen with other infections like the common cold, researchers say.

In most cases, the smell loss lasts only a few weeks, but for more than 12% of COVID-19 patients, olfactory dysfunction persists in the form of ongoing reduction in the ability to smell (hyposmia) or changes in how a person perceives the same smell (parosmia).

To gain insight into COVID-19-induced smell loss, the current authors explored the molecular consequences of SARS-CoV-2 infection in golden hamsters and in olfactory tissue taken from 23 human autopsies.

Hamsters represent a good model, being mammals that both depend more on the sense of smell than humans, and that are more susceptible to nasal cavity infection.

The study results build on the discovery over many years that the process which turns genes on involves complex 3-D relationships, where DNA sections become more or less accessible to the cell's gene-reading machinery based on key signals, and where some DNA chains loop around to form long-range interactions that enable the stable reading of genes.

Some genes operate in chromatin "compartments" -- protein complexes that house the genes that are open and active, while others are compacted and closed, as part of the "nuclear architecture."

In the current study, experiments confirmed that SARS-CoV-2 infection, and the immune reaction to it, decreases the ability of DNA chains in chromosomes that influence the formation of olfactory receptor building to be open and active, and to loop around to activate gene expression.

In both hamster and human olfactory neuronal tissue, the research team detected persistent and widespread downregulation of olfactory receptor building.

Other work posted by these authors suggests that olfactory neurons are wired into sensitive brain regions, and that ongoing immune cell reactions in the nasal cavity could influence emotions, and the ability to think clearly (cognition), consistent with long COVID.

Experiments in hamsters recorded over time revealed that downregulation of olfactory neuron receptors persisted after short-term changes that might affect the sense of smell had naturally recovered.

The authors say this suggests that COVID-19 causes longer-lasting disruption in chromosomal regulation of gene expression, representing a form of "nuclear memory" that could prevent the restoration of OR transcription even after SARS-CoV-2 is cleared.

In a next step, the team is looking into whether treating hamsters with long COVID with steroids can restrain damaging immune reactions (inflammation) to protect nuclear architecture.

Along with tenOever, authors of the current study from the Department of Microbiology at NYU Langone Health were Justin Frere, Rasmus Moeller, Skyler Uhl, and Daisy Hoagland.

Also leading the study were corresponding authors Jonathan Overdevest and Stavros Lomvardas from the Mortimer B. Zuckerman Mind, Brain and Behavior Institute at Columbia University.

Additional contributors included Marianna Zazhytska, Albana Kodra, Hani Shayya, Stuart Firestein, Peter Canoll, and James Goldman.

Also making important contributions were study authors John Fullard and Panos Roussos of the Icahn School of Medicine at Mt. Sinai; Arina Omer of Baylor Genetics in Houston; and Qizhi Gong of the Department of Cell Biology and Human Anatomy, School of Medicine, University of California at Davis.

Funding for the study was provided by National Institutes of Health grants NIDCD 3R01DC018744-01S1 and U01DA052783, as well as by a Howard Hughes Medical Institute Faculty Scholar Award and the Zegar Family Foundation.